Abstract 1054
Background
Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody (mAb), with functional Fc domain capable of inducing ADCC, that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors. Cosibelimab is being evaluated in a multicenter phase 1 study (NCT03212404) in pts with advanced cancers. We present preliminary safety, efficacy and PK data.
Methods
Pts were ≥18 years old with advanced cancers and adequate organ function. In dose escalation, pts received cosibelimab administered intravenously at sequential fixed doses of 200 mg, 400 mg, or 800 mg every 2 weeks (q2w) or 1200 mg every 3 weeks (q3w) using a 3 + 3 design. Following dose escalation, multiple tumor-specific expansion cohorts are being enrolled at 800 mg q2w to further evaluate safety and efficacy.
Results
As of April 23, 2019, 65 pts (47M/18F, median age 64 years) with diverse tumor types received cosibelimab in dose escalation and expansion cohorts. Cosibelimab has demonstrated acceptable tolerability with no dose‐limiting toxicities. Treatment‐related adverse events (AEs) occurred in 32/65 (49%) pts, most commonly rash (n = 9, 14%) and fatigue (n = 6, 9%). Treatment‐related grade ≥3 AEs occurred in 5/65 (8%) pts, all grade 3, and included anemia, asthenia, hypertension, hyponatremia, and high blood pressure (n = 1 [2%] each). Cosibelimab demonstrated linear PK with features consistent with marketed anti-PD-L1 mAbs. Thirty-six pts were response evaluable of which 10/36 (28%) pts achieved a partial response by RECIST 1.1 criteria (including cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma), 17/36 (47%) pts achieved stable disease, and 24/36 (67%) pts experienced target lesion reductions versus baseline. Forty-two pts remain on treatment (range, 1-17+ mos).
Conclusions
Cosibelimab has demonstrated a safe and well-tolerated safety profile with evidence of durable anti‐tumor activity in several advanced cancers, and linear PK. Cosibelimab is being further evaluated in multiple tumor-specific expansion cohorts. Updated results will be presented.
Clinical trial identification
NCT03212404.
Editorial acknowledgement
Legal entity responsible for the study
Checkpoint Therapeutics, Inc.
Funding
Checkpoint Therapeutics, Inc.
Disclosure
P.R. Clingan: Research grant / Funding (institution): Merck Sharp & Dohme Corp; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Bristol Myers; Research grant / Funding (institution): Checkpoint Therapeutics, Inc. A.M. Mant: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. G.E. Richardson: Research grant / Funding (institution): Novotech; Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Alphapharm; Research grant / Funding (institution): Checkpoint Therapeutics. D.M. Kowalski: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. P. Koralewski: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. I. Lugowska: Research grant / Funding (institution): Checkpoint Therapeutics, Inc.; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol Myers; Honoraria (self): Merck; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self): Amgen; Honoraria (self): Janssen; Honoraria (self), Research grant / Funding (institution): Novartis. A. Dechaphunkul: Speaker Bureau / Expert testimony: Roche; Travel / Accommodation / Expenses: Eisai; Research grant / Funding (institution): Checkpoint Therapeutics. C. Charoentum: Research grant / Funding (institution): Roche; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Checkpoint Therapeutics. A. Sookprasert: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Honoraria (self): Eisai; Research grant / Funding (institution): Checkpoint Therapeutics, Inc. V. Sriuranpong: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self): Sanofi; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Boehringer; Honoraria (self), Research grant / Funding (institution): Taiho; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck Sharp & Dohme; Honoraria (self): Bristol Myers; Advisory / Consultancy: Amgen; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Checkpoint Therapeutics. A. Akopov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. V. Kozlov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. N. Fadeeva: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. B. Kasparov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. N.V. Kovalenko: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. V. Oschepkov: Research grant / Funding (institution): Checkpoint Therapeutics, Inc. L. Gorelik: Shareholder / Stockholder / Stock options, Full / Part-time employment: Checkpoint Therapeutics, Inc. Y. Kunes: Shareholder / Stockholder / Stock options: Checkpoint Therapeutics, Inc. J. Oliviero: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Checkpoint Therapeutics, Inc. D.L. Harris: Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Checkpoint Therapeutics; Research grant / Funding (institution): Targovax.
Resources from the same session
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract
4369 - Biomarker testing of lung cancer in Spain
Presenter: Delvys Rodriguez Abreu
Session: Poster Display session 1
Resources:
Abstract